Skip to main content
Medexus Pharmaceuticals Inc. logo

Medexus Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · MDP ISIN · CA58410Q2036 LEI · 8945002TBEYY0HLH1M19 TSX Manufacturing
Open in API
Filings indexed 638 across all filing types
Latest filing 2024-12-02 Regulatory Filings
Country CA Canada
Listing TSX MDP

About Medexus Pharmaceuticals Inc.

https://www.medexus.com/en_US

Medexus Pharmaceuticals, Inc. is an innovative specialty pharmaceutical company engaged in the development and commercialization of treatment solutions. The company utilizes a highly scalable North American business model, leveraging a fully integrated infrastructure encompassing commercial operations, supply chain, regulatory affairs, and a dedicated salesforce. Medexus focuses on building a portfolio of specialty and rare disease products across key therapeutic areas, including hematology, hematology-oncology, allergy, dermatology, and rheumatology. Its mission is to deliver quality healthcare products to patients and healthcare professionals.

Recent filings

Filing Released Lang Actions
Other material contracts - English.pdf
Regulatory Filings Classification · 12% confidence The document is titled “Fourth Amendment to Commercialization and Supply Agreement” and is a legal amendment to an existing supply and commercialization contract between parties. It does not present financial results, call transcript, proxy materials, AGM materials, dividend notices, or any of the other specific categories. It is not regulatory or disclosure by a public company about their financials or governance – it’s a private contract amendment. There is no dedicated contract amendment category, so under the fallback rules this is classified as a general regulatory filing (RNS).
2024-12-02 English
News release - English.pdf
Capital/Financing Update Classification · 90% confidence The document is a press release announcing the successful completion of negotiations between Medexus Pharmaceuticals and the pan-Canadian Pharmaceutical Alliance (pCPA) for the drug Trecondyv (treosulfan for injection) in Canada. It discusses the negotiation process, regulatory recommendations, and future steps for public reimbursement. The document includes forward-looking statements and background information about the drug and the company. There are no financial statements, detailed financial performance data, or regulatory filings such as annual or quarterly reports. The content focuses on a corporate update related to product commercialization and reimbursement negotiations, which is typical of a Capital/Financing Update or similar corporate announcement. It is not an earnings release, annual report, or regulatory filing. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-11-18 English
Decision Document (Final).pdf
Regulatory Filings
2024-11-15 English
Non-issuer's submission to jurisdiction and appointment of agent.pdf
Regulatory Filings
2024-11-15 English
Undertaking to file documents and material contracts.pdf
Regulatory Filings
2024-11-15 English
Decision Document (Preliminary).pdf
Regulatory Filings Classification · 95% confidence The document is a receipt from the Ontario Securities Commission for the filing of a Preliminary Short Form Base Shelf Prospectus dated November 8, 2024. It is a regulatory acknowledgment of a prospectus filing, not the prospectus itself or a detailed financial report. The document length is short (1106 characters) and it serves as a formal receipt rather than a report or announcement of financial results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory documents that do not fit other specific categories.
2024-11-08 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.